Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
05 May 1987Website:
http://immucell.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Thu, 27 Jun 2024 16:10:21 GMTDividend
Analysts recommendations
Institutional Ownership
ICCC Latest News
PORTLAND, Maine , June 05, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today provided a regulatory update on the status of its product development initiative for Re-Tain ®.
PORTLAND, Maine, June 04, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) will be conducted virtually on Thursday, June 13, 2024, at 9:30 AM ET, as previously disclosed in its Proxy Statement filed with the Securities and Exchange Commission (“SEC”) on April 26, 2024.
ImmuCell Corporation (NASDAQ:ICCC) will be hosting a conference call to discuss their Q1 2024 financial results on May 15, 2024 at 9:00 AM ET. Company representatives include Joe Diaz and Michael Brigham. Participants in the call include Michael Potter, Maynard Fernandez, and Sean Kirkwood. The operator will begin the call with a welcome message.
Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ET Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ET
PORTLAND, Maine, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2023 after the market closes on Thursday, August 10, 2023. The Company has scheduled a conference call the next morning, Friday, August 11, 2023, at 9:00 AM ET to review its second quarter financial results.
ImmuCell Corporation (NASDAQ:ICCC ) Q1 2023 Earnings Conference Call May 12, 2023 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Conference Call Participants Operator Good morning, and welcome to ImmuCell Corporation Reports First Quarter 2023 Unaudited Financial Results Conference Call. All participants will be in a listen-only mode.
PORTLAND, Maine, May 04, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2023 after the market closes on Thursday, May 11, 2023. The Company has scheduled a conference call the next morning, Friday, May 12, 2023, at 9:00 AM ET to review its first quarter financial results.
What type of business is ImmuCell?
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
What sector is ImmuCell in?
ImmuCell is in the Healthcare sector
What industry is ImmuCell in?
ImmuCell is in the Biotechnology industry
What country is ImmuCell from?
ImmuCell is headquartered in United States
When did ImmuCell go public?
ImmuCell initial public offering (IPO) was on 05 May 1987
What is ImmuCell website?
https://immucell.com
Is ImmuCell in the S&P 500?
No, ImmuCell is not included in the S&P 500 index
Is ImmuCell in the NASDAQ 100?
No, ImmuCell is not included in the NASDAQ 100 index
Is ImmuCell in the Dow Jones?
No, ImmuCell is not included in the Dow Jones index
When does ImmuCell report earnings?
The next expected earnings date for ImmuCell is 09 August 2024